Product Overview

With the advent of multiple variants of fungus & constant development of microbial resistance against various antifungal medications, effective oral antifungal is the need of the hour.
Recent studies with oral Itraconazole have shown an effective result against various dermatophytosis.
So, we are introducing a novel formulation of SUBA (Superior bioavailable) itraconazole that utilizes a unique spray-drying/double drying technology producing microencapsulated form of nanoparticles of itraconazole dispersed in a polymer matrix instead of conventional crystalline form to enhance the solubility & bioavailability of the poorly soluble oral medication

RECOMMENDED FOR-

Chronic recalcitrant endemic & systemic dermatophytosis (yeast & moulds)

Lesser patient variability than conventional itraconazole.
100% patients were above the therapeutic threshold.
Itraconazole SB was safe & well-tolerated.
Up to 90% bioavailable with improved overall absorption & consistent plasma levels.
Therapeutic levels are achieved & maintained.
Delivery of consistent blood levels of itraconazole for lower patient variability.
As the drug is released in the small intestine so absorption of it is not reduced.
It comes in dosage of 65 mg & 130 mg.
This technology delivers nearly double the bioavailability of conventional 100 mg.
Itraconazole capsules in a smaller 65 mg dose.

Conventional Itraconazole	SUBA Itraconazole
No advanced delivery technology	Novel SUper BioaAailable delivery technology
Poor bioavailability	~2x bioavailability
Affected by food	Maintained uniform therapeutic levels in fed & fasted state
Affected by co-administration of PPIs (antacids)	Absorption not affected by co-administration of PPIs
Low pH required (stomach) for release & absorption of drug	Non-reliance on acidic pH of stomach due to SUBA technology

Patients ≥ 18 years.
Immunocompromised & non-immunocompromised patients.
Should be non-pregnant and not breastfeeding (and not planning to become pregnant).
Significant liver dysfunction.
Documented intolerance, allergy or hypersensitivity to itraconazole.
Known history or presence of congestive cardiac failure.

This medicine works by killing the fungus or yeast and preventing its growth.
Itraconazole capsule is used to treat fungal infections, such as aspergillosis (fungal infection in the lungs), blastomycosis, or histoplasmosis.

Wherever conventional 100 mg twice daily dose is given 65 mg would do
SUBA 130 mg maybe given as single dose wherever conventional 200 mg is prescribed

Nausea, rash, vomiting, headache, diarrhoea, fatigue, abdominal pain etc. can be seen which has an incidence of >1%.
Hence patient’s reaction towards the medication must be observed as a precautionary measure.

Co-administration with certain drugs which can interact with itraconazole/patients having hypersensitivity towards itraconazole